Navigation Links
Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
Date:5/20/2008

d 2003, and received at least one course of chemotherapy. The study evaluated differences in OS between patients who received treatment that was deemed responsive, intermediate-responsive or non-responsive based on ChemoFx test results.

Of the 206 patients analyzed:

-- Median OS of Assay non-responsive patients was 39.2 months

-- Median OS of Assay intermediate-responsive patients was 62.5 months

-- Median OS of Assay responsive patients was 80.4 months

When accounting for cancer stage and debulking -- the reduction of tumor size due to surgery or radiation treatment -- overall survival was significantly associated with the ChemoFx Assay and the cancer stage. In the model simulating improved survival if patients were treated with a therapy that caused a greater tumor response, median OS of patients treated with an Assay non-responsive drug could be improved from 39.2 to 62.5 months and median OS of patients treated with an Assay intermediate-responsive drug could be improved from 62.5 to 101.3 months.

"People with cancer often require additional treatment after receiving the standard of care chemotherapy. ChemoFx Assay can provide valuable information that could spare the patient from unnecessary toxicity associated with a potentially ineffective treatment," said Sean McDonald, CEO Precision Therapeutics. "The goal of ChemoFx is to empower patients and physicians with additional diagnostic information to help determine the most appropriate course of therapy for each individual patient."

This retrospective, multi-center analysis is a published abstract at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and is available at http://www.asco.org.

About ChemoFx(R)

ChemoFx is a decision support tool that measures a specific patient's tumor response to various types, combinations and doses of chemotherapy selected by the patient's phy
'/>"/>

SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...wire-FirstCall/ -- Smith & Nephew ( SNN, LSE: ...he signing of a technology development contract wi...y lead to the creation of a fracture fixation syst...limbs of soldiers who sustain battlefield injuries...rojects Agency (DARPA), the central research and d...
(Date:11/19/2009)...e/ -- In response to an ever-increasing number of ..., Operation Pangea II, involving 24 countries, was...nization,s International Medical Products Anti-Cou...ngers of buying medicines online. ,, The week l...sts and the seizure of thousands of potentially ha...
(Date:11/19/2009).../ -- Riverain Medical announced today that the com...cal imaging distributor Christie Group to offer So...ay CAD. The exclusive agreement will bring Dayton,...adian market through Christie Group,s established ...ed Chest Imaging increases the clarity of digital ...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Riverain Medical Partners With The Christie Group In Canada To Offer SoftView Enhanced Chest Imaging and OnGuard Chest X-Ray CAD Technologies 2Finance Committee Begins Markup Lab Fee Converted to Medicare Cut 14238 1Max Neeman International to Open Phase I IIa Unit 14233 1Max Neeman International to Open Phase I IIa Unit 14233 2Medicinal products susceptible to dose dumping should be fully tested 58148 1
... Analysis Demonstrates Robust, Highly Statisticall...umab Compared to Rebif(R), CAMBRIDGE, Mass., Oct....nounced that top-line, three-year data from a,comp... with Rebif(R),(interferon beta- 1a) for the treat...kend at the 23rd Congress of the European Committe...
...ata to be Submitted for Presentation at 2007 San A...mposium, REDWOOD CITY, Calif., Oct. 11 Genomic H...aging results from a study of,Oncotype DX in postm...or,positive breast cancer conducted by the Southwe...ute clinical trials cooperative group. Oncotype DX...
Other Medicine Technology:Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 2Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 3Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 4Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 5Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 6Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis 7Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients 2Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients 3
(Date:11/20/2009)...ov. 20 The following is...of the Nevada Health Care Association: ,, "The ... thanks Senate Majority Leader Harry Reid for his ...rd our goal of protecting every Nevada seniors, on...serving the strength and viability of our state,s ...
(Date:11/20/2009)...readings in children with chronic kidney disease o...or,s office visits increasing a child,s risk for ... Johns Hopkins Children,s Center and other institu...the Journal of American Society of Nephrology. ,...s obtained during regular doctor visits to reading...
(Date:11/20/2009)...ne-third buying 90-day supply, study finds , ...a three-month supply of prescription drugs is up t..., according to a new study. , U.S. researchers ... between 2000 and 2005, and found that patients wh...th supply saved an average 29 percent in out-of-po...
(Date:11/20/2009)... Bread addresses increased food insecurity as many...Newswire-USNewswire/ -- Project Bread, the state,s...s from its upcoming annual status report on hunger...ibed in this report, caused by high unemployment, ...ling with hunger. Food insecurity has found its wa...
(Date:11/20/2009)..., La., Nov. 20 The ... warned that Louisianians could experience higher ...sals being considered by Congress should become la...fficer for LAHP, "Louisiana health plans have supp...eginning of the national debate. Our plans have o...
Breaking Medicine News(10 mins):Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
...difference in chemotherapy treatment; some critics...t. 8 (HealthDay News) -- A 2003 overhaul of Medica... for their services did not alter cancer patients,...rapy treatments to begin and traveling the same di...
...al in Northeast Ohio to make quality and safety li...ron City,Hospital has been named a "Leapfrog Top H...Ohio and one of just 33 adult hospitals in the nat...hat,assesses hospital quality and safety. Accordi...
...MFIELD, Conn., Oct. 8, 2007 /PRNewswire-FirstCall/...y concern among America,s,local governments, most ...management programs targeting their stated top hea...d sponsored by leading,employee benefits carrier, ...
...olon cancer is proving much more convenient than t...and a study of almost 2,000 patients has shown it ...sease. , Standard chemotherapy can be incredibly...week for the injections and then have three weeks ...
...es Epidemic Opportunity, BRENTWOOD, Tenn., Oct. 8...red a growth equity investment of $50 million from...s investment, NEA General,Partners Chip Linehan an...supplies market," said Richard Pinson, Simplex,Cha...
...d soul, PAGOSA SPRINGS, Colo., Oct. 8 1.1 billio...; another 1.5 billion don,t have,adequate sanitati...he world,s poorest people access to,safe water and...na,s northern regions are acutely deprived, with o...
Other Medicine News:Health News:Medicare Changes Didn't Alter Cancer Care 2Health News:Medicare Changes Didn't Alter Cancer Care 3Health News:Medicare Changes Didn't Alter Cancer Care 4Health News:Summa Health System's Akron City Hospital Named 'Leapfrog Top Hospital' for 2007 2Health News:ICMA/CIGNA Survey: U.S. Cities and Counties Begin to Focus on Health Risks and Costs 2Health News:ICMA/CIGNA Survey: U.S. Cities and Counties Begin to Focus on Health Risks and Costs 3Health News:ICMA/CIGNA Survey: U.S. Cities and Counties Begin to Focus on Health Risks and Costs 4Health News:Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates 2Health News:Make a Difference This Holiday Season 2
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: